Cbd for seizures
Pro Research Analysisby 
Searched over 200M research papers
Cannabidiol (CBD) for Seizures: A Comprehensive Overview
Introduction to CBD and Seizure Management
Cannabidiol (CBD), a non-psychoactive compound derived from the Cannabis sativa plant, has garnered significant attention for its potential in managing epilepsy and reducing seizure frequency. Unlike tetrahydrocannabinol (THC), CBD does not induce euphoria, making it a promising candidate for therapeutic use in epilepsy without the risk of abuse or intrusive side effects 12.
Efficacy of CBD in Epilepsy Treatment
Reduction in Seizure Frequency
Several studies have demonstrated the efficacy of CBD in reducing seizure frequency in patients with various forms of epilepsy. A systematic review and meta-analysis involving patients with Lennox-Gastaut syndrome (LGS) and Dravet syndrome (DS) showed that CBD significantly reduced seizure frequency compared to placebo. Specifically, a 20 mg/kg/day dose of CBD resulted in a 19.9 percentage point reduction in seizure frequency . Another study confirmed these findings, reporting a 44% reduction in drop seizures in LGS patients treated with CBD compared to a 22% reduction in the placebo group .
Broader Epileptic Conditions
Beyond LGS and DS, CBD has shown promise in treating other epileptic conditions. For instance, a review highlighted the effectiveness of CBD in managing seizures in patients with tuberous sclerosis complex and other developmental and epileptic encephalopathies, such as CDKL5 deficiency disorder and Aicardi syndrome . This broad efficacy suggests that CBD could be beneficial across a wide range of epilepsy disorders.
Safety and Adverse Events
Common Adverse Events
While CBD is generally well-tolerated, it is associated with some adverse events. The most commonly reported side effects include somnolence, decreased appetite, diarrhea, and increased serum aminotransferases 124. In a study on LGS, 86% of patients on CBD experienced adverse events compared to 69% in the placebo group, with serious adverse events reported in 9 CBD patients .
Long-term Safety
Long-term studies have also supported the safety profile of CBD. An open-label extension trial for patients with tuberous sclerosis complex reported that CBD was well-tolerated over an extended period, with a similar adverse event profile to shorter trials. The most common adverse events were diarrhea, decreased appetite, and elevated liver enzymes .
Comparative Efficacy: CBD-Rich Extracts vs. Purified CBD
A meta-analysis comparing CBD-rich extracts to purified CBD products found that patients treated with CBD-rich extracts reported better outcomes. Specifically, 71% of patients using CBD-rich extracts reported improvement in seizure frequency compared to 46% of those using purified CBD. Additionally, CBD-rich extracts were associated with fewer adverse effects, suggesting a potential synergistic effect of other phytocompounds present in the extracts .
Mechanisms of Action
The anti-seizure effects of CBD are believed to be mediated through multiple mechanisms, including modulation of ionic channels, neurotransmitter transporters, and various receptors. Notably, CBD does not act directly on cannabinoid receptors but may involve antagonism of G protein-coupled receptor 55 (GPR55) and desensitization of transient receptor potential of vanilloid type 1 (TRPV1) channels 18. Additionally, CBD has been shown to inhibit AMPA receptor activity, reducing neuronal excitability and improving seizure outcomes in animal models .
Conclusion
CBD has emerged as a promising adjunctive treatment for various forms of epilepsy, demonstrating significant efficacy in reducing seizure frequency and a generally favorable safety profile. While more research is needed to fully understand its mechanisms and long-term effects, current evidence supports the use of CBD, particularly in treatment-resistant epilepsy. The potential benefits of CBD-rich extracts over purified CBD also warrant further investigation to optimize therapeutic outcomes.
Sources and full results
Most relevant research papers on this topic